Subtype
Malignant Vascular Neoplasm
CI-CAN-00001191Explore in graph →
36 active trials4 approved drugs4 evidence items
- NCIt
- C7390
Loading cancer entity…
Subtype
CI-CAN-00001191Explore in graph →
Clinical trials
193 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (21)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07576725 | Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial | not yet recruiting | Phase 2 | 50 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05797662 | A Study of Propranolol to Treat Kaposi Sarcoma | not yet recruiting | Phase 2 | 25 | AIDS Malignancy ConsortiumNETWORK | 5 | Aug 11, 2026 | clinicaltrials |
| NCT07684287 |
| A Phase 2 Study of Sirolimus for Injection (Albumin-bound) in Patients With Progressive or Symptomatic Epithelioid Hemangioendothelioma |
| not yet recruiting |
| Phase 2 |
| 40 |
| CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY |
| 1 |
| Jul 6, 2026 |
| clinicaltrials |
| NCT07539454 | Nirogacestat in Patients With Kaposi Sarcoma | not yet recruiting | Phase 2 | 28 | AIDS Malignancy ConsortiumNETWORK | 1 | May 28, 2026 | clinicaltrials |
Data updated 13 days agoSource updated Sep 17, 2026source: clinicaltrials